Detalhe da pesquisa
1.
TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q).
Br J Haematol
; 204(4): 1243-1248, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38083865
2.
Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia.
Haematologica
; 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38299605
3.
Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities.
Ann Hematol
; 103(1): 117-123, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38030891
4.
Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML.
Ann Hematol
; 103(6): 1941-1945, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38634915
5.
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations.
Acta Haematol
; 147(2): 175-185, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38052186
6.
TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity.
Cancer
; 129(2): 175-180, 2023 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36397669
7.
Drivers of deep molecular response and long-term outcomes in patients with core binding factor acute myeloid leukemia.
Am J Hematol
; 98(12): E360-E363, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37705256
8.
Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes.
Curr Treat Options Oncol
; 24(5): 387-408, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36966266
9.
Targeting the cluster of differentiation 47/signal-regulatory protein alpha axis in myeloid malignancies.
Curr Opin Hematol
; 29(1): 44-52, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34854834
10.
Disease-related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlates.
Cancer
; 128(19): 3495-3501, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35942592
11.
Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations.
Cancer
; 128(21): 3880-3887, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36107670
12.
Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes.
Br J Haematol
; 198(4): 713-720, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35751140
13.
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.
Blood
; 136(24): 2812-2823, 2020 12 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32730593
14.
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.
Blood
; 136(2): 157-170, 2020 07 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32347921
15.
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.
J Natl Compr Canc Netw
; 20(2): 106-117, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35130502
16.
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes.
Blood
; 133(10): 1039-1048, 2019 03 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30670444
17.
Acquisition of IDH2 mutations in relapsed/refractory AML is associated with worse patient outcomes.
Eur J Haematol
; 107(6): 609-616, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407254
18.
Genomic characteristics and prognostic significance of co-mutated ASXL1/SRSF2 acute myeloid leukemia.
Am J Hematol
; 96(4): 462-470, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33502020
19.
Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Int J Mol Sci
; 22(18)2021 Sep 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34576266
20.
Novel therapies in myelodysplastic syndromes.
Curr Opin Hematol
; 27(2): 58-65, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31972686